The Use of Platelet-rich Plasma in the Treatment of Chronic Anal Fissure
1 other identifier
interventional
460
1 country
1
Brief Summary
use of platelet rich plasma had good effect in treating chronic wounds. healing of perianal fissure could be prolonged and associated with pain. injection of platelet rich plasma under fissure base and edges had the advantage of improved fissure healing and reduction of the pain, with minimal side effects.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Oct 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
September 30, 2022
CompletedFirst Submitted
Initial submission to the registry
November 14, 2022
CompletedFirst Posted
Study publicly available on registry
May 1, 2023
CompletedMay 3, 2023
May 1, 2023
1.8 years
November 14, 2022
May 1, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Healing of fissure
Complete epithelization of fissure base
3 months
Secondary Outcomes (2)
Duration of pain
3 months
Pain change
3 months
Study Arms (2)
Nitroglycerin only
ACTIVE COMPARATORapplication of local Nitroglycerin ointment 2% (Recto-Relief Nitroglycerin Ointment, 30 g) applied twice daily.
platelet rich plasma injection
EXPERIMENTALinjection of platelet rich plasma under fissure base and edges
Interventions
venous blood drown from the patient, centrifugation and separation of platelet rich plasma, injection under fissure and edges base.
application of the ointment twice daily
Eligibility Criteria
You may qualify if:
- chronic anal fissure for more than three months
You may not qualify if:
- medical comorbidity
- inflammatory bowel disease
- tuberculosis fissure
- HIV infected patients
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Al-Kindy Teaching Hospital
Baghdad, 10011, Iraq
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Taghreed Alhaidari, C.A.B.O.G
Al-Kindy College of Medicine
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 14, 2022
First Posted
May 1, 2023
Study Start
October 1, 2020
Primary Completion
July 30, 2022
Study Completion
September 30, 2022
Last Updated
May 3, 2023
Record last verified: 2023-05
Data Sharing
- IPD Sharing
- Will not share